Unresectable colorectal cancer
Conditions
Interventions
cetuximab plus 5-FU/LV
Sponsors
Aichi Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histological proven unresectable colorectal cancer KRAS wild Measurable lesions according to RECIST criteria Following previous treatment - refractory to 5-FU - failure or refractory or intolerant of irinotecan - refractory or failure to oxaliplatin Adequate interval from previous treatments Adequate organ function Age of 20 years or older ECOG performance status 0-2 Expected more than 8 weeks survival Written informed consent from patient
Exclusion criteria
Exclusion criteria: Symptomatic brain metastasis Sever wattery diarrhea Paralytic or mechanical bowel obstruction Confirmed or suspected infection Severe pulmonary disease Severe comorbidity Pregnant or possibly pregnant, and nursing women Sever neurologic disease Receiving atazanavir sulfate Past history of monoclonal antibody sever allergy Past history of 5-FU/LV sever allergy Past history of treatment with Anti-EGFR Other conditions not suitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| disease control rate, progression free survival, overall survival, toxicity, QOL | — |
Countries
Japan
Contacts
Public ContactTakashi Ura
Aichi Cancer Center Hospital Department of Clinical Oncology
Outcome results
None listed